株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨粗鬆症市場・予測分析

Osteoporosis Market and Forecast Analysis

発行 Datamonitor Healthcare 商品コード 498958
出版日 ページ情報 英文 118 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
骨粗鬆症市場・予測分析 Osteoporosis Market and Forecast Analysis
出版日: 2017年03月05日 ページ情報: 英文 118 Pages
概要

当レポートでは、骨粗鬆症の上市済み薬剤およびパイプラインの動向を調査し、疾患の概要、地域/主要国別の患者数の推移と予測、主な上市済み薬剤のプロファイル、パイプラインの動向などをまとめています。

疫学:骨粗鬆症

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報ソース・調査手法
  • 予測:骨減少症
  • 予測:骨粗鬆症
  • 疫学者の考察
  • 強み・制約
  • 付録

上市済み薬剤:骨粗鬆症

  • エグゼクティブサマリー
  • 製品概要
  • ビスフォスフォネート
  • エストロゲン・SERM
  • カルシトニン
  • その他の薬剤クラス
  • 製品プロファイル: Forteo
  • 製品プロファイル: Prolia

パイプライン:骨粗鬆症

  • エグゼクティブサマリー
  • 臨床パイプライン:概要
  • コンパレーター治療
  • 近年中止された薬剤
  • 製品プロファイル (後期): Evenity
  • 製品プロファイル (後期): abaloparatide

図表

目次
Product Code: DMKC4728

Disease Overview

Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease. It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture, and the associated complications represent a huge socioeconomic burden. Treatment of osteoporosis can be a challenge as bone loss is essentially symptomless until a fracture occurs, which can lead to difficulties with diagnosis and patient compliance.

TABLE OF CONTENTS

EPIDEMIOLOGY: OSTEOPOROSIS

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast: Osteopenia
  • Forecast: Osteoporosis
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix: Additional Sources

MARKETED DRUGS: OSTEOPOROSIS

  • Executive Summary
  • Product Overview
  • Bisphosphonates
  • Estrogens and SERMs
  • Calcitonin
  • Other Drug Classes
  • Product profile: Forteo
  • Product profile: Prolia

PIPELINE: OSTEOPOROSIS

  • Executive Summary
  • Clinical Pipeline Overview
  • Comparator Therapy
  • Recently Discontinued Drugs
  • Product profile (late stage): Evenity
  • Product profile (late stage): abaloparatide

LIST OF FIGURES

  • Figure 1: Trend in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 2: Absolute change in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 3: Trend in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 4: Absolute change in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 5: Age-specific growth in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, 2016-36
  • Figure 6: Age-specific growth in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, 2016-36
  • Figure 7: Forteo for osteoporosis - SWOT analysis 68 Figure 8: Datamonitor Healthcare's drug assessment summary of Forteo for osteoporosis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Forteo for osteoporosis 79 Figure 10: Prolia for osteoporosis - SWOT analysis
  • Figure 11: Datamonitor Healthcare's drug assessment summary of Prolia for osteoporosis
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Prolia for osteoporosis
  • Figure 13: Evenity for osteoporosis - SWOT analysis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Evenity for osteoporosis
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Evenity for osteoporosis
  • Figure 16: Abaloparatide for osteoporosis - SWOT analysis 113 Figure 17: Datamonitor Healthcare's drug assessment summary of abaloparatide for osteoporosis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of abaloparatide for osteoporosis

LIST OF TABLES

  • Table 1: Sources used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
  • Table 2: Sources not used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
  • Table 3: Total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 4: Age-specific total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016
  • Table 5: Gender-specific total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016
  • Table 6: Total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 7: Age-specific total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016
  • Table 8: Gender-specific total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016
  • Table 9: Key marketed drugs for osteoporosis
  • Table 10: Bisphosphonate class overview
  • Table 11: Estrogens/SERMs class overview
  • Table 12: Salmon calcitonin class overview
  • Table 13: Other drug classes overview Disease Coverage | Osteoporosis 5 © Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
  • Table 14: Forteo drug profile
  • Table 15: Forteo pivotal trial data in osteoporosis
  • Table 16: Forteo late-phase trial data in osteoporosis
  • Table 17: Prolia drug profile
  • Table 18: Prolia pivotal trial data in osteoporosis
  • Table 19: Prolia late-phase trial data in osteoporosis
  • Table 20: Phase III pipeline products in development for osteoporosis
  • Table 21: Forteo drug profile 91 Table 22: Forteo trial data in osteoporosis
  • Table 23: Late-stage compounds that were recently discontinued for osteoporosis
  • Table 24: Odanacatib drug profile 95 Table 25: Odanacatib trial data in osteoporosis
  • Table 26: Evenity drug profile 100 Table 27: Evenity Phase III trial data in osteoporosis
  • Table 28: Evenity ongoing Phase III trials in osteoporosis
  • Table 29: Abaloparatide drug profile
  • Table 30: Abaloparatide Phase III trial data in osteoporosis
Back to Top